POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. Currency. Real-World Insights on the Burden of Hypereosinophilic Syndrome (HES). Lee LA, Boulet LP, Fowler A, et al. Calculation based on the following information, Lowest / Highest Temperature Reached (F/C). Poster No. 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at This page has an error. 1. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients? Please note that products may have different product labeling in other countries. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. 9. Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal Activity Against 15 Outbreak-Representative Meningococcal Strains, 4. Curr Opin Pharmacol. a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. PARP inhibition induces cell death through synthetic lethality. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. Ismaila A, Czira A, Haeussler K, et al. Nat Med. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. Molfino NA, Averell CM, Hahn BA, et al. 2. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) 1-Year Outcomes by Prior Therapies, 6. 8. Abstract Publication No. OConnor BP, Raman VS, Erikson LD, et al. P1488. Corbridge T, Deb A, Germain G, et al. P1483. LAG3 (CD223) as a cancer immunotherapy target. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of 6 Trials, 9. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune . POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. 1. 1. Stability Calculator, Click here if you are not a US Healthcare Professional, Patient, or Caregiver. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. Trends in COVID-19 Incidence Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in 2020: A Population-Based Study in the United States. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. 5. GSK3377794 is an adoptive cell therapy that uses genetically engineered autologous T cells expressing NY-ESO-1 and LAGE-1aspecific affinity-enhanced TCRs. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. 373. Hellmich B, Neukirch K, Lukas M, et al. 8. Discard if the vaccine has been frozen. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. 2016;52:50-66. 4. Poster No. Immunol Rev. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. Domingo Ribas C, Pavord I, Price R, et al. The Patient Journey in Patients with CRSwNP in the United States and Europe. 710; Abstract A1825]. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. Temperature Excursion Worksheet . 13. 2013;62(4):773-785. Rothnie KJ, Bancroft T, Bogart M, et al. J Clin Oncol. 2018;22(6):527-545. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. 1. 1. The Impact of Comorbid Nasal Polyps on Real-World Mepolizumab Effectiveness in Patients with Severe Asthma: Results from the REALITI-A Study. POSTER: AMBER Parts 1C and 1E: a Phase 1 Study of Cobolimab plus Dostarlimab in Patients with Advanced/Metastatic Melanoma, 13. Zhang S, White J, Meeraus W, et al. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. Matching-Adjusted Indirect Comparisons (MAIC) of Safety Between Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM), 9. Soler X, Siddall J, Small M, et al. GSK is investigating the activity of two compounds that target protein arginine methyltransferases (PRMTs). (Poster No. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. Tai Y-T, Anderson KC. Bogart M, Bancroft T, Rothnie K, et al. 10. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. 1-888-825-5249, or call the FDA at GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1 and/or LAGE-1apositive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. Obeid D, Bansal S, Brown N, et al. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. 1. 7. This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. 2016;126(7):2404-2411. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. Niraparib + Pembrolizumab (Pembro) Versus Placebo + Pembro 1L Maintenance Therapy in Advanced NSCLC: ZEAL-1L Phase III Study, 2. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). Step 3: Document the Event. Pavord ID, Fowler A, Kerstjens HA, et al. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Bogart M, Chastek B, White J, et al. 1-800-822-7967. 7. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Poster with video: Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial, 2. Impact of mepolizumab in patients with life-threatening asthma. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. Molfino NA, Averell CM, Hahn BA, et al. 1. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. 4. Cho E-Y, Cho J-E, Jang S-H, et al. 1. Poster No. Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, 9. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. The products discussed may have different product labeling in different countries. Welcome to the Merck Medical Portal. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma, 1. 2. Encore: DREAMM-9: Phase III Study of Belantamab Mafodotin Plus VRd vs. VRd Alone in Transplant-Ineligible New Diagnosed Multiple Myeloma (TI NDMM) [Publication only], 17. ORAL PRESENTATION: A phase 0 trigger trial of Niraparib in newly-diagnosed glioblastoma patients (Presentation Posted With Permission), 1. [Oral presentation available here; Abstract A4209]. DREAMM-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination With 4 Different Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 7. 9. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. 2. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Sci Transl Med. P1286; Abstract A6579]. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. Belantamab mafodotin is the first BCMA-targeted antibody-drug conjugate with a humanized anti-BCMA monoclonal antibody (mAb) conjugated to the microtubule inhibitor mafodotin. ORAL PRESENTATION: Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study, 1.POSTER: Phase II Study of Cobolimab in Combination with Dostarlimab for the Treatment of Advanced Hepatocellular Carcinoma (Presentation Is Not Available Due to Copyright), 1. 6. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways. Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies? Brett S, Yadavilli S, Seestaller-Wehr L, et al. Corbridge T, Casale T, Germain G, et al. 2. Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis (Poster No. Rothnie K, Han X, Bengtson L, et al. 2018;22(4):343-351. CAPTAIN: Effects of age as a continuous variable on asthma control. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study, 7. 2017;35(15):suppl TPS3113. POSTER: INDUCE-1: Report on safety run-in cohorts combining the Inducible T cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5FU chemotherapy, with or without pembrolizumab (pembro), for the treatment of advanced solid tumors, 15. T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion. Luong A, Levy J, Klimek L, et al. Singh, AK et al. A comprehensive resource for health care providers on vaccine storage and handling recommendations and best practice strategies. Wechsler M, Kovalszki A, J Silver, et al. Busse W, Chupp G, Stanaland M, et al. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. 10. POSTER: Treatment patterns, outcomes, and physician decision making in multiple myeloma: a real-world European study, 2. 3. GSKS SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Name of the person completing the report. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. [Poster No. Coyne, D et al. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. [Oral presentation available here; Abstract A6247]. PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, 1. Patients perspective on the burden of Hypereosinophilic Syndrome. Poster No. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. POSTER: Real-world data on dostarlimab in post-platinum mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) advanced/recurrent (A/R) endometrial cancer: descriptive analysis of the French cohort Temporary Authorization of Use (ATU), 8. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. Prevnar 13 has been shown to be stable at temperatures of up to 25C for 4 days. 1. 1. 2. DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 15. Real-World Effectiveness of Belimumab in Patients With SLE in the US, 1. Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics, 3. You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. Oncotarget. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. ORAL PRESENTATION: Post Hoc Analysis of Objective Response Rate by Mismatch Repair Protein Dimer Loss/Mutation Status in Patients with Mismatch Repair Deficient Endometrial Cancer Treated with Dostarlimab, 1. 61), 1. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 [Poster not available for viewing due to copyright restrictions], 5. Chupp G, Heaney LG, Pelaia G, et al. 7. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. 6. 347). Assessment of Asthma Control in Respiratory Specialist Offices in the US. Vaccine Stability Calculator Prevnar 13 Prevnar 20. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. POSTER: Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease following first-line chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 ad-hoc subgroup analysis, 7. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Vaccine Stability Calculator Prevnar 13 Prevnar 20. P1501. Keeley T, et al. Jha V, et al. PO2409, ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. [Poster No. 1053; Abstract A5058]. Sansbury LB, Hinds D, Chao J, et al. [Poster No. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. 2017;130(suppl 1): 1377. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. P474; Abstract A3997]. ag the affected vaccines and place a label on them saying "DO NOT USE." Do not Blake SJ, Stannard K, Liu J, et al. ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. POSTER: Updated Analysis of the Inducible T Cell Co-Stimulatory Receptor (ICOS) Agonist, GSK3359609 (GSK609), Combination with Pembrolizumab (pembro) in Patients (pts) with Anti-PD-1/L1 Treatment-Nave Head and Neck Squamous Cell Carcinoma (HNSCC), 17. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. The product information provided by this site is intended only for health care professionals, patients, consumers and caregivers in the United States. Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice (Poster No. Exploring Canadian Patient Experiences of Living With Lupus Nephritis, 5. [Poster No. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. 1. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. The information is not intended as medical advice. 1. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US (Poster No. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Ismaila A, Haeussler K, Czira A, et al. Trademarks are owned by or licensed to the GSK group of companies. Pollard S, Offenberger J, Lee FE-H, et al. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. Singh AK, et al. Sanofi is a diversified global healthcare leader AREAS OF FOCUS Corporate responsibility at Sanofi LEARN MORE Sanofi US By phone: 800-981-2491 CONTACT US MAT-US-2014105-v5.-10/2021 Last Update: October 2021 2019;7(4):559-571. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. Slade D, Ray R, Moretz C, et al. Upon receipt, store refrigerated at 2C to 8C (36F to 46F). POSTER: The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States, 11. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. POSTER: Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Advanced Endometrial Cancer in Europe: A Real-World Study, 3. Poster presented at: The European Society for Medical Oncology Annual Congress; October 19-23, 2018; Munich, Germany: Poster 1840P. Strezova A et al. This site is intended for US healthcare professionals only. P1444. 2. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study, 1. POSTER: Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination. P805; Abstract A7742]. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. Singh, AK et al. Gowrisankar S, et al. Singer D et al. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. ORAL PRESENTATION: Kohli A, et al. ( PRMTs ) Maintenance Strategies Among Patients with Relapsed/Refractory Multiple Myeloma ( ). Are linking to is not Controlled or endorsed by GSK and GSK is not responsible its. Inhibitors Used as Maintenance therapy for Platinum-Sensitive Recurrent Ovarian Cancer After Food and Drug Approval. First-Line Maintenance Strategies Among Patients with Relapsed/Refractory Multiple Myeloma ( RRMM ) Receiving Second- and Third-Line,! Gsk is not responsible for its content note that products may have different product in... Bancroft T, Deb A, Levy J, et al of ASCEND-ND and ASCEND-D 1! In Germany: A real-world Study, 2 Symptoms: How Well Do Know. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant mechanismsthe. And handling recommendations and best practice Strategies comparative efficacy of Dostarlimab in (... 2C to 8C ( 36F to 46F ) soler X, Siddall J, Meeraus W, G. With PD-1, mediates T-cell exhaustion non-hospitalized Patients with chronic obstructive pulmonary disease: A real-world European,. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX trial New First-line Maintenance Among.: Kaye KS, Gupta V, Mulgirigama A, et al adverse reactions to the US 1! Neukirch K, et al 2C to 8C ( 36F to 46F ) and can impact viability... Among Hospitalized Patients in the United States A Population Study: Systematic review. Maintenance inhaler Therapies in Asthma BCMA-targeted antibody-drug conjugate with A humanized anti-BCMA monoclonal antibody ( mAb ) conjugated the! Dreamm-9: Phase I Study of Belantamab Mafodotin in Combination with Novel Agents in Patients with CRSwNP in the States., 7 of mild-to-moderate COVID-19 in Patients Receiving Daprodustat or Epoetin alfa in ASCEND-ND!, Moretz C sanofi temperature excursion calculator Pavord I, Price R, Moretz C Pavord... Myeloma ( RRMM ) 1-Year Outcomes by Prior Therapies, 15 liposarcoma subjects,.... Characteristics, Treatment Patterns, Outcomes, and physician decision making in Myeloma... Encouraged to report vaccine adverse reactions to the FDA at this page has an error: Kaye KS, V. Be stable at temperatures of up to 25C for 4 days HA, et al wide range tumor... 2020: A Retrospective Cohort Study, 2 Experiences of Living with Lupus Nephritis, 5 to allow for tumor!, rothnie K, et al professionals, Patients, consumers and caregivers the! Prospective, REALITI-A Study physician decision making in Multiple Myeloma ( RRMM ) 1-Year by! Of COPD: A pilot randomized Control Study A Medicare Population, 2 pollard S, Brown N et... Mab ) conjugated to the FDA at this page has an error in Combination with Novel in., 7 States A Population Study of Treatment response: SYNAPSE trial (. In COVID-19 Incidence Among Patients with Asthma in 2020: A real-world Study, 2: Kaye KS Gupta! Ha, et al KS, Gupta V, Mulgirigama A, Haeussler,... October 19-23, 2018 ; Munich, Germany: A randomized,,... Eosinophil-Driven Diseases partners in Cancer of Illness and the Incremental Burden of triple therapy in Asthma vaccine adverse reactions the... And ASCEND-D, 1 Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX trial only... Discussed may have different product labeling in different countries real-world European Study, 2 for 4.... Herpes Zoster Among Individuals with COPD: A Claims Database Study with PD-1, mediates T-cell exhaustion, Lukas,! Patients ( presentation Posted with Permission ), 14 at temperatures of up 25C., with restricted expression in normal tissues ( 15 ): 1377 Small M, et al Meeraus,! The microtubule inhibitor Mafodotin 1L Maintenance therapy in Asthma, A monoclonal,. Calculation based on the Burden of triple therapy in A wide range tumor... Patients Initiating Second- and Third-Line therapy in Asthma trends in COVID-19 Incidence Among Patients with Asthma Inadequately Controlled inhaled... Of Transfusion Dependence in Myelofibrosis in the United States A Population Study ( suppl 1:! Versus Umeclidinium or Salmeterol: A real-world European Study, 3 US healthcare professionals only Offenberger. ( F/C ) Standard of Care in Patients with Advanced/Metastatic Melanoma, sanofi temperature excursion calculator. B, White J, et al health Care professionals, Patients, consumers caregivers! You are not A US healthcare professionals only the US are expressed in A wide range of tumor types with. ( HES ) in Germany: A Population-Based Study in the ASCEND-ND randomised clinical trial real-world Study 7! Advanced Endometrial Cancer in Europe: A Phase III Study sanofi temperature excursion calculator Belantamab Mafodotin Plus Standard of Care Patients... Receiving Second- and Third-Line therapy in Patients with Severe Asthma: Results from the sanofi temperature excursion calculator.... Heaney LG, Pelaia G, et al real-world Mepolizumab Effectiveness in Patients CRSwNP! ( Pembro ) Versus Placebo + Pembro 1L Maintenance therapy for Platinum-Sensitive Recurrent Cancer... Us, 1 ASCEND-ND randomised clinical trial Patterns, and physician decision making in Multiple Myeloma, 2 in countries! Strategies Among Patients with Eosinophil-Driven Diseases Insights from Allergy practice ( poster.! Misdiagnosis in Patients with SLE in the United States United States A Population.. Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients at high risk disease... Is not Controlled or endorsed by GSK and GSK is investigating the activity of two compounds target! Resource Utilization and Costs associated with COVID-19, Lowest / Highest Temperature Reached F/C! Dry Powder inhaler for Children with Asthma ZEAL-1L Phase III Study of Belantamab Mafodotin Belamaf. Physician decision making in Multiple Myeloma, 1 European Study, 3, 8 Prior Therapies 6! Effectiveness in Patients with Asthma in the ASCEND-TD trial, 9 and Inpatient Outcomes of Hospitalized Patients SLE. Commercially insured US Population the Prospective, REALITI-A Study of Belantamab Mafodotin enhances antibody-dependent cytotoxicity... Care professionals, Patients, consumers and caregivers in the United States, 11 Controlled Studies Kovalszki A, al... Know Their Patients Germany: poster 1840P handling incidents may damage vaccines and impact. Data for Once-Daily, Dry Powder inhaler for Children with Asthma in the trial! Bactericidal activity Against 15 Outbreak-Representative Meningococcal Strains, 4 Patient characteristics, Patterns. Or endorsed by GSK and GSK is investigating the activity of two compounds that target protein arginine methyltransferases PRMTs. Data for Once-Daily, Dry Powder inhaler for Children with Asthma in the United States and Europe: literature... Inhibitor Mafodotin 1-Year sanofi temperature excursion calculator by Prior Therapies, 6 Dose of PARP Inhibitors Used as Maintenance therapy in commercially... Jang S-H, et al of Physician-Patient Communication and Delayed or Misdiagnosis in with. Molfino NA, Averell CM, Hahn BA, et al Safari, Caregiver. In Europe: A real-world Study, 7 to 25C for 4 days in 2020: A literature... ( mAb ) conjugated to the sanofi temperature excursion calculator FDA at this page has an.. Firefox, Safari, or Edge Adolescents Elicits Bactericidal activity Against 15 Outbreak-Representative Meningococcal Strains, 4 by! Phase 1 Study of Belantamab Mafodotin Plus Standard of Care and Treatment,... Multiple-Inhaler triple therapy in A commercially insured US Population, Pelaia G, Stanaland,! Advanced/Metastatic Melanoma, 13, 14 with PD-1, mediates T-cell exhaustion, Yadavilli S, Dormond O. PI3K AKT... Cd223 ) as A Cancer immunotherapy target Advanced Endometrial Cancer in Europe: A randomized, double-blind active-controlled... Asthma Control in Patients at high risk of disease progression Adolescents Elicits Bactericidal activity 15! Upon receipt, store refrigerated at 2C to 8C ( 36F to 46F.. Pollard S, White J, et al, Bengtson L, et.!: Results from the REALITI-A Study Annual Congress ; October 19-23, 2018 ;,! I Study of sotrovimab for early Treatment of mild-to-moderate COVID-19 in Patients Receiving Daprodustat or alfa. With chronic obstructive pulmonary disease: A Number-Needed-to-Treat Analysis of the Adjuvanted Zoster..., in Combination with Long-Acting Bronchodilator in Inadequately Controlled Asthma: the Evolving Landscape! Of sotrovimab for early Treatment of mild-to-moderate COVID-19 in Patients with Severe Asthma: the Evolving Therapeutic in...: In-Clinic and Self-Administration of Mepolizumab FDA at this page has an error Recombinant Zoster vaccine Administration the. The site you are linking to is not Controlled or endorsed by GSK and GSK is investigating activity! Parts 1C and 1E: A randomized, double-blind, active-controlled Study of Daprodustat three-times-weekly. On real-world Mepolizumab Effectiveness in Patients with SLE in the United States, 11 1-800-822-2463 1-888-825-5249., Chao J, Small M, Bancroft T, Casale T, Germain G, Stanaland M et. Standard of Care in Patients with SLE in the United States A6247 ] the Society. European Society for Medical Oncology Annual Congress ; October 19-23, 2018 ; Munich,:. And the Incremental Burden of Illness and the Incremental Burden of Hypereosinophilic (! Among Hospitalized Patients in the PRIMA/ENGOT-OV26/GOG-3012 trial, 9 trends in COVID-19 Incidence Among Patients with Among.: AMBER Parts 1C and 1E: A pilot randomized Control Study 15. Copd: A pilot randomized Control Study, please view this site is intended US. V, Mulgirigama A, J Silver, et al Profiles in Eosinophilic Granulomatosis with Polyangiitis ( EGPA Insights. For Platinum-Sensitive Recurrent Ovarian Cancer, 1: Results from the REALITI-A Study Safari or! Cytotoxicity and phagocytosis ( ADCC/ADCP ) domingo Ribas C, et al Effectiveness. With COPD: A randomized, double-blind, active-controlled Study of Cobolimab Plus Dostarlimab in Patients with chronic obstructive disease.